. . "Inhibitory cholinesteras maj\u00ED p\u0159\u00EDzniv\u00FD vliv na kognitivn\u00ED, funk\u010Dn\u00ED i behavior\u00E1ln\u00ED projevy Alzheimerovy choroby (AD) a v sou\u010Dasn\u00E9 dob\u011B p\u0159edstavuj\u00ED t\u00E9m\u011B\u0159 v\u00FDhradn\u011B jedinou skupinu l\u00E9\u010Div pou\u017E\u00EDvan\u00FDch pro terapii tohoto onemocn\u011Bn\u00ED. T\u0159i z nich jsou schv\u00E1leny k u\u017E\u00EDv\u00E1n\u00ED americkou agenturou Food and Drug Administration \u2013 donepezil, rivastigmin a galantamin. Krom\u011B inhibitor\u016F cholinesteras se d\u00E1le pou\u017E\u00EDv\u00E1 memantin, kter\u00FD je p\u0159edstavitelem N-methyl-D-aspart\u00E1tov\u00FDch (NMDA) nekompetitivn\u00EDch antagonist\u016F. Takrin (9-amino-1,2,3,4-tetrahydroakridin) se stal prvn\u00EDm schv\u00E1len\u00FDm inhibitorem cholinesteras pro l\u00E9\u010Dbu AD. Jeho ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky, zejm\u00E9na hepatotoxicita a gastrointestin\u00E1ln\u00ED pot\u00ED\u017Ee, v\u0161ak limituj\u00ED jeho dal\u0161\u00ED vyu\u017Eit\u00ED. Nov\u00E9 deriv\u00E1ty takrinu jsou intenzivn\u011B zkoum\u00E1ny ve snaze naj\u00EDt l\u00E1tky s ni\u017E\u0161\u00ED toxicitou a postihuj\u00EDc\u00ED v\u00EDce patologick\u00FDch mechanism\u016F \u00FA\u010Dastn\u00EDc\u00EDch se AD. P\u0159edkl\u00E1dan\u00E1 pr\u00E1ce sumarizuje dosud publikovan\u00E9 strukturn\u00ED aspekty takrinov\u00FDch deriv\u00E1t\u016F a zam\u011B\u0159uje se na jejich vybran\u00E9 biologick\u00E9 vlastnosti. Jednotliv\u00E9 slou\u010Deniny jsou roz\u010Dlen\u011Bny dle strukturn\u00EDch aspekt\u016F do t\u0159\u00ED z\u00E1kladn\u00EDch skupin, kter\u00E9 jsou diskutov\u00E1ny."@cs . "RIV/62690094:18470/12:50000691" . . "Takrin a jeho deriv\u00E1ty v terapii Alzheimerovy choroby"@cs . "\u0160pilovsk\u00E1, Katar\u00EDna" . . . . "Tacrine and its derivatives in the therapy of Alzheimer\u2019s disease"@en . . . . "\u010Cesk\u00E1 a slovensk\u00E1 farmacie" . . "61" . "Soukup, Ond\u0159ej" . "1210-7816" . "Tacrine and its derivatives in the therapy of Alzheimer\u2019s disease"@en . "Cholinesterase inhibitors have beneficial effects on the cognitive, functional, and behavioural symptoms of Alzheimer\u2019s disease (AD). Up to date, they represent almost the only drugs approved by the U.S. Food and Drug Administration agency for AD treatment. The group involves donepezil, rivastigmine and galantamine. Apart from the above mentioned cholinesterase inhibitors, memantine is used for AD treatment as well acting as N-methyl-D-aspartate (NMDA) non-competitive antagonist. Tacrine (9-amino-1,2,3,4-tetrahydro-acridine) was the first cholinesterase inhibitor approved for symptomatic AD treatment. However, its several side effects (hepatotoxicity and gastrointestinal discomfort) limited tacrine further use. Recently, novel tacrine analogues are extensively investigated in endeavour to find less toxic compounds with the \u201Cmulti-target directed ligand\u201D profile affecting more AD pathological mechanisms. The following study summarizes the knowledge of up to date published tacrine analogues, their structural aspects and biological properties. According to structural aspects, tacrine derivatives are divided into three groups, where they are discussed."@en . "Takrin a jeho deriv\u00E1ty v terapii Alzheimerovy choroby"@cs . "Ku\u010Da, Kamil" . "Kor\u00E1be\u010Dn\u00FD, Jan" . "Takrin a jeho deriv\u00E1ty v terapii Alzheimerovy choroby" . "I, P(GAP303/11/1907)" . "[B8B27F965562]" . . "Mus\u00EDlek, Kamil" . "CZ - \u010Cesk\u00E1 republika" . "1"^^ . "18470" . "173231" . "Takrin a jeho deriv\u00E1ty v terapii Alzheimerovy choroby" . "5" . "inhibitor; acetylcholinesterase; tacrine and its derivatives; Alzheimer\u2019s disease"@en . . "RIV/62690094:18470/12:50000691!RIV13-MSM-18470___" . . "Benek, Ond\u0159ej" . . . "6"^^ . . "12"^^ . "Inhibitory cholinesteras maj\u00ED p\u0159\u00EDzniv\u00FD vliv na kognitivn\u00ED, funk\u010Dn\u00ED i behavior\u00E1ln\u00ED projevy Alzheimerovy choroby (AD) a v sou\u010Dasn\u00E9 dob\u011B p\u0159edstavuj\u00ED t\u00E9m\u011B\u0159 v\u00FDhradn\u011B jedinou skupinu l\u00E9\u010Div pou\u017E\u00EDvan\u00FDch pro terapii tohoto onemocn\u011Bn\u00ED. T\u0159i z nich jsou schv\u00E1leny k u\u017E\u00EDv\u00E1n\u00ED americkou agenturou Food and Drug Administration \u2013 donepezil, rivastigmin a galantamin. Krom\u011B inhibitor\u016F cholinesteras se d\u00E1le pou\u017E\u00EDv\u00E1 memantin, kter\u00FD je p\u0159edstavitelem N-methyl-D-aspart\u00E1tov\u00FDch (NMDA) nekompetitivn\u00EDch antagonist\u016F. Takrin (9-amino-1,2,3,4-tetrahydroakridin) se stal prvn\u00EDm schv\u00E1len\u00FDm inhibitorem cholinesteras pro l\u00E9\u010Dbu AD. Jeho ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky, zejm\u00E9na hepatotoxicita a gastrointestin\u00E1ln\u00ED pot\u00ED\u017Ee, v\u0161ak limituj\u00ED jeho dal\u0161\u00ED vyu\u017Eit\u00ED. Nov\u00E9 deriv\u00E1ty takrinu jsou intenzivn\u011B zkoum\u00E1ny ve snaze naj\u00EDt l\u00E1tky s ni\u017E\u0161\u00ED toxicitou a postihuj\u00EDc\u00ED v\u00EDce patologick\u00FDch mechanism\u016F \u00FA\u010Dastn\u00EDc\u00EDch se AD. P\u0159edkl\u00E1dan\u00E1 pr\u00E1ce sumarizuje dosud publikovan\u00E9 strukturn\u00ED aspekty takrinov\u00FDch deriv\u00E1t\u016F a zam\u011B\u0159uje se na jejich vybran\u00E9 biologick\u00E9 vlastnosti. Jednotliv\u00E9 slou\u010Deniny jsou roz\u010Dlen\u011Bny dle strukturn\u00EDch aspekt\u016F do t\u0159\u00ED z\u00E1kladn\u00EDch skupin, kter\u00E9 jsou diskutov\u00E1ny." . "http://www.prolekare.cz/ceska-slovenska-farmacie-clanek/takrin-a-jeho-derivaty-v-terapii-alzheimerovy-choroby-39300" . . .